The Pharmacy Times® Psoriatic Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Ron Lanton III, Esq, President, True North Political Solutions, makes predictions about how dealings with biosimilars may change in 2018.
Tofacitinib (Xeljanz/Xeljanz XR) improves disease severity for patients with psoriatic arthritis.
Up to 90% of patients with psoriasis develop plaque on their nails, palms of the hands, and soles of the feet.
Hay fever and asthma are dependent on allergens that stimulate the immunoglobulin E pathway, which is not the case with atopic dermatitis.
Ixekizumab found to provide significant improvement in joint symptoms for patients not previously treated with a biologic disease-modifying antirheumatic drug.
Patients with moderate-to-severe nail psoriasis treated with secukinumab experienced significant improvement in the Nail Psoriasis Severity Index.
Secukinumab (Cosentyx) treatment observed to improve the signs and symptoms of psoriatic arthritis.
New Drug Applications filed for halobetasol propionate and tazarotene lotion, a topical treatment for plaque psoriasis.
Treatment for psoriatic arthritis may impact symptoms and patient-reported outcomes.
Patients with active psoriatic arthritis experience significant work instability based on disease activity.
Several modalities found to be effective in the triage of psoriasis patients with musculoskeletal symptoms, according to a study presented at the 2017 American College of Rheumatology meeting.
Risankizumab treats moderate to severe chronic plaque psoriasis.